RELMADA THERAPEUTICS, INC. Prepaid Expense and Other Assets, Current
RELMADA THERAPEUTICS, INC. (RLMD) had Prepaid Expense and Other Assets, Current of $798.09 thousand as of 2016-06-30, per its 10-K filed 2016-09-09.
Discontinued › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2016-09-09
- 2016-06-30: Prepaid Expense and Other Assets, Current $798.09K.
- 2015-06-30: Prepaid Expense and Other Assets, Current $1.50M.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2016-06-30 | $798.09K 10-K · filed 2016-09-09 |
| 2015-06-30 | $1.50M 10-K · filed 2016-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |